Original Research Article

Drug resistance in tuberculosis-resurvey in Wardha district, India after implementation of revised national TB control program

Supriya Meshram1,*, Pratibha Narang2, Farah Mohammed3, Rahul Narang4, NS Gomathi5, Ajay Dawale6

1 Dept. of Microbiology, Jawaharlal Nehru Medical College, Sawangi Meghe, Wardha, Maharashtra, India
2 Dept. of Microbiology, Mahatma Gandhi Institute of Medical Sciences, Sewagram, Wardha, Maharashtra, India
3 Intermediate Reference Laboratory, Nagpur, Maharashtra, India
4 AIIMS - All India Institute of Medical Sciences, Bibinagar, Telangana, India
5 National Institute of Research in Tuberculosis, Chennai, Tamil Nadu, India
6 District TB Centre, Wardha, Maharashtra, India

ARTICLE INFO

Article history:
Received 15-05-2021
Accepted 05-07-2021
Available online 01-09-2021

Keywords:
Resurvey
New Pulmonary TB patients
Drug Resistance

ABSTRACT

Level of drug resistance among new TB patients indicates the efficacy of any control programme. A drug resistance survey, as a part of global study in new pulmonary tuberculosis (NPTB) patients, was conducted in Wardha district, India under WHO /IUTLD in 2001, before the implementation of the Revised National Tuberculosis Control Programme (RNTCP) which was implemented in the district in 2002.

Objective: The present study was conducted in Wardha district in 2014-2015, thirteen years after the implementation of RNTCP, and the drug resistance in Mycobacterium tuberculosis isolates from NPTB patients was compared to the results of 2001 survey. The methodology used was same in both the surveys.

Material and Methods: In addition to 132 isolates from Wardha, the study also included 112 isolates from adjoining city, Nagpur and total of 244 sputum isolates were subjected to drug sensitivity by standard 1% proportion method on Lowenstein Jensen’s medium. In addition molecular typing of resistant strains was done.

Results: In Wardha, compared to 2001 survey, overall susceptibility to first line drugs was higher (94.7% vs 80.2%); and resistance to streptomycin (3% vs 7.6%) and isoniazid (2.2% vs 15.2%) were significantly lower (p < 0.05). MDR was 0.75% against 0.50% in the earlier study but the difference was statistically not significant. Only two MDR isolate were recovered, of which only one was from Wardha.

Conclusion: After the implementation of RNTCP in Wardha District, drug resistance in new PTB patients has shown a decline and MDR continues to be low reflecting upon the efficiency of the program.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Tuberculosis (TB) remains a major global health problem, responsible for ill health among millions of people each year resulting in devastating social and economic impact. The development of drug resistance in Mycobacterium tuberculosis (MTB), specially multidrug resistance (MDR) and extensive drug resistance has further dealt a major blow to tuberculosis control programmes leading to increased morbidity and mortality. MDR-TB is a man-made problem mainly related to poor case management in the earlier stages of treatment after which accurate and rapid detection of the resistant strains is critical for providing appropriate treatment to the patient and to intercept the transmission of drug resistant
tuberculosis in the community.

The Revised National Tuberculosis Control Programme (RNTCP) was launched in India in 1997 in a phased manner as the ongoing National Tuberculosis Programme (NTP), started in 1962, had many lacunae. RNTCP adopted the internationally recommended Directly Observed Treatment Short Course (DOTS) strategy where the first line anti TB drugs (isoniazid H, rifampicin R, pyrazinamide Z and ethambutol E) were given thrice weekly under direct supervision New patients received a total of 6 months therapy with 2H3R3Z3E3 in the intensive phase followed by 4H3R3 in the continuation phase. The old National Tuberculosis control program followed daily regimen for a duration of 18 months.

In Wardha district RNTCP was introduced in 2002. In order to assess the impact of any intervention it is necessary to generate data and compare it with the relevant data already available from previous studies. The Department of Microbiology at the Mahatma Gandhi Institute of Medical Sciences (MGIMS), Sewagram Wardha, India was involved with the Tuberculosis Research Centre (currently National Institute for Research in Tuberculosis), Chennai, India, in conducting the WHO/IUTLD global project on anti-tuberculous drug resistance surveillance in 2000-2001 when sputum isolates from new pulmonary tuberculosis (NPTB) patients were subjected to first line anti tuberculosis drug susceptibility testing (DST) by 1% proportion method on Lowenstein-Jensen (LJ) medium. Level of multidrug resistance (MDR ie., resistance to isoniazid and rifampicin) reported at that time was 0.5%. In a recently concluded study by the Indian Council of Medical Research on recurrence of TB among NPTB cases, of which the same department was a part of, Mycobacterium tuberculosis (MTB) isolates from sputum samples of new pulmonary TB patients from the same region were tested by 1% proportion method on LJ medium in the Mycobacteriology laboratory which is certified under the RNTCP for DST using solid media. The aim of the present study was therefore to conduct first line anti TB drug sensitivity on all the Mycobacterium tuberculosis isolates from Wardha district and compare the sensitivity results with the previous pre RNTCP data generated in the WHO/IUTLD study. These results could give us the status of drug resistance in the study area and an insight into any change in prevalence of drug resistance after the introduction of RNTCP.

Both the studies followed the same well established protocols and in both only new cases were recruited. In addition to Wardha, samples from NPTB patients were also collected from the adjoining city of Nagpur and drug sensitivity was also put up for ofloxacin.

The secondary objective was to subject the resistant isolates to line probe assay (LPA) in order to substantiate the phenotypic results of rifampicin and isoniazid resistance and to get the mutational patterns prevalent in this region of central India.

2. Material and Methods

This prospective cross sectional study was conducted from 2014-2016 after obtaining due ethical clearance from the Institutional Ethics Committee and informed consent from the patients. A new PTB patient was defined as a case of pulmonary TB positive for acid fast bacilli (AFB) in the sputum and who had either never taken anti-tuberculosis drugs or had taken them for less than one month.

Sputum samples were collected in sterile containers from new smear positive pulmonary tuberculosis patients reporting to our hospital in Wardha district and at Wardha and Nagpur Tuberculosis Units (TUs). A TU is the subdistrict level managerial unit responsible for RNTCP implementation in its geographical jurisdiction inhabited by 2,50,000-5,00,000 population. During the study period, all sites, all consecutive new patients were screened by the RNTCP technician for acid fast bacilli and those who gave written consent were inducted into the study. The sputum samples were collected by the employed social worker and brought on motorbikes to the laboratory on the same day. The sample coming directly to the laboratory from the hospital were also included after taking due consent. In the laboratory the samples were cultured as per RNTCP protocol.

The sputum was first concentrated by modified Petroff’s method and then cultured on two Lowenstein Jensen (LJ) slopes and incubated for 8 weeks before reporting as negative. The isolates were identified as M. tuberculosis (MTB) by rapid immune-chromatographic MPT64Ag test (BD Bioline, Korea). All MTB isolates were subjected to drug susceptibility testing by 1% proportion method on LJ medium (LJ-DST) for streptomycin, isoniazid, rifampicin, ethambutol and ofloxacin as per the standard recommendations and interpretations.

All the drugs were procured from Sigma laboratories. The final concentrations of drugs used were: streptomycin (dihydrostreptomycin sulfate) 4μg/ml, isoniazid 0.2 μg/ml, ethambutol 2 μg/ml, rifampicin 40 μg/ml and ofloxacin 2 μg/ml. The slopes were incubated at 37°C and read at 4 weeks and then at 6 weeks. The test was considered as invalid if no growth was seen on drug free medium even after 8 weeks of incubation.

Isolates resistant to isoniazid and rifampicin by proportion method were subjected to Line Probe Assay (LPA) in order to compare the results with LJ-DST and to see the mutational patterns.

2.1. Line probe assay

The WHO approved GenoType® MTBDRplus, (Hain’s Life Science Nehren, Germany) was used for confirmation of resistance to rifampicin and isoniazid and to elucidate, as per the kit protocol, the mutational patterns for these two
drugs in the clinical isolates. The genes investigated were katG, inhA, for isoniazid and rpoB for rifampicin. This part of the study was carried out at the RNTCP certified Intermediate Reference Laboratory for Tuberculosis at Nagpur.

An isolate was considered a) Susceptible when there was presence of wild-type bands and absence of mutant bands; b) Resistant when there was absence of one or more wild-type bands with or without presence of mutant bands and c) hetero-resistant when both the wild type bands and mutant bands were present, due to hybridization of both wild-type and the corresponding mutant probes indicating heterogeneous population or mixed infection with sensitive and resistant strain. 10

The H37Rv (ATCC 27294) laboratory strain was used as the susceptible control both for the proportion method as well as LPA. In addition, extraction negative controls and master mix negative controls were included with every batch.

3. Results

A total of 244 M. tuberculosis isolates, from 280 new sputum smear positive patients from Wardha (132) and Nagpur TU (112), were subjected to drug susceptibility test by LJ-DST. Sixteen (6.55%) isolates were resistant to various drugs. Any resistance was maximum to streptomycin (4.5%), followed by isoniazid (2.45%), rifampicin (0.81%) and ethambutol (0.4%) Prevalence of drug resistance in both the TUs was similar for all drugs except for streptomycin which was more in Nagpur, but the difference was statistically not significant. (Table 1)

No mono resistance to rifampicin was detected and only 2 isolates were MDR (0.81%), one each from Wardha and Nagpur (Table 1). Resistance to ofloxacin among the 244 isolates was low (0.81%) with only 2 resistant strains, one each from Wardha and Nagpur.

To achieve the secondary objective all the 16 isolates resistant to any drug by proportion method were subjected to LPA for the detection of isoniazid and rifampicin resistance. Results for both the drugs were in line with the phenotypic results and no additional isolate resistant to either rifampicin or isoniazid was detected. The two isolate detected as MDR by LJ–DST were also detected as such by LPA and for rifampicin, one of the isolate showed the mutation at S531L while the other had mutational pattern with unusual mutational pattern with all missing codons in WT4, WT6, WT7 and WT8 bands bands.(Table 2)

The mutation patterns of isolates that were resistant to isoniazid by LJ-DST are also shown in (Table 2). Three isoniazid mono resistant strains showed katG mutation at S315T1 while the fourth depicted low level resistance with mutation in inhA gene at C15T. Out of the two MDR strains, one of them showed high level isoniazid resistance with mutation in katG at S315T2 while the other isolate showed low level resistance with mutation in inhA at C15T. In all, four out of six isolates showed high isoniazid resistance while two had low isoniazid resistance.

4. Discussion

The main objective of the study was to find out the level of drug resistance among new PTB patients in the two study areas of Wardha and Nagpur and to compare the results of the current study with the data of 2001 available for Wardha district under the WHO/IUATLD surveillance project. 4

The present study has been conducted thirteen years after the previous study 4 and twelve years after the implementation of RNTCP in the Wardha district in July 2002. 3 The comparison of Wardha figures with the earlier study show a significant fall in the resistance to streptomycin and isoniazid (Table 3). Drug resistance for isoniazid has fallen from 15.2% to 2.27% (p< 0.05) and streptomycin has decreased from 7.6% to 3.03% (p<0.05). Resistance to rifampicin shows a slight increase from 0.5% to 0.75% but the difference is not statistically significant. The figure 0.75% with ethambutol is also not significant. There is also a significant fall in mono resistance to streptomycin and isoniazid (p<0.05)(Table 3).

Though no earlier surveillance data from Nagpur TU is available for comparison, where again RNTCP was implemented in May 2002, the current study found that drug resistance per se was low in the region. In the WHO/IUATLD project, 4 a total of 197 MTB isolates from NPTB patients were processed for drug susceptibility and 80.2% were reported to be sensitive to all the four first line drugs tested. In the present study 244 isolates from similar patients from Nagpur and Wardha were tested and 93.44% were sensitive to all the four drugs. Whereas any resistance to streptomycin was 7.6%, isoniazid 15.2%, ethambutol 1% in the earlier study, the similar figures for the Wardha and Nagpur together were 4.5%, 2.45%, and 0.40% respectively which are considerably low (Table 3). No mono resistance to rifampicin was detected in either study and MDR was 0.5% (1/197) in the previous survey compared to 0.81% (2/244) in the present study (Table 3) which is again not statistically significant (p>0.05). The low level of resistance in NPTB patients has great implication as it not only means that the RNTCP control programme with DOTS has been running well, it also means that even in the absence of laboratory report on drug susceptibility, majority of newly diagnosed patients in the area can be started on the first line regimens resulting in minimal risk of treatment failure.

A study from Delhi in 2008-2009 using same 1% proportion method (LJ-DST) on 177 isolates from 218 NPTB cases, has also reported on similar lines. 11 They have found 1.1% prevalence of MDR TB with 6.2% resistance to isoniazid, 1.1% to rifampicin, 3.4% to ethambutol, 2.3% to streptomycin and none to pyrazinamide. The author have also stated that after the implementation of RNTCP and
Table 1: Drug resistance pattern of *M. tuberculosis* culture isolates from Wardha and Nagpur when tested by 1% proportion method on LJ medium.

| Pattern of Drug Resistance | Number resistant (tested n=244) | Number resistant | Number resistant |
|----------------------------|----------------------------------|------------------|------------------|
|                            | % Wardha (tested n=132)          | Wardha (tested n=112) | Nagpur (tested n=112) |
| S                          | 2 1.51                          | 5 4.46            |
| H                          | 1 0.75                          | 1 0.89            |
| OF                         | 1 0.75                          | 0 0               |
| SH                         | 1 0.75                          | 0 0               |
| SE                         | 1 0.75                          | 0 0               |
| SOF                        |                                 |                  |
| HR                         | 2 0.81                          | 1 0.89            |
| Sensitive to all           | 228 93.44                       | 125 94.69         | 103 91.96        |

S- streptomycin, H-isoniazid, R- rifampicin, E-ethambutol, OF-ofloxacin

Table 2: Pattern of rifampicin and isoniazid resistant isolates as detected by Geno Type MTBDRplus

| S.No | Gene | Band | Codon region | Mutations | No of isolates |
|------|------|------|--------------|-----------|----------------|
| 1.   | katG | WT   | 315          | S315T1 (MUT-1) | 3              |
| 2.   | inhA | WT-1 | -15          | C15T (MUT-1)   | 2              |
|      |      |      |              |            |                |
|      | rpoB | WT-8 | 530-533      | S531L (MUT-3) | 1              |
|      | Kat G| WT   | 315          | S315T2 (MUT2) |                |
| 2.   |      | Missing bands | 513-519 |            | 1              |
|      |      | WT3/WT4 |            |            |                |
|      |      | WT5/WT6 |            |            |                |
|      |      | WT-7   | 518-525      |            |                |
|      |      | WT-8   | 526-529      |            |                |
|      |      |         | 530-533      |            |                |
|      |      | inhA   | -15          | C15T (MUT-1)   |                |

Table 3: Comparison of drug resistance in the present study (2015-2016) with WHO/IUATLD (2001) study from Wardha.

| Any resistance Drugs | WHO/IUATLD 2001 figures for resistance (A) (n=197) | Wardha 2015-2016 figures for resistance (B) (n=132) | p value Between (A) and (B) | Nagpur plus Wardha 2015-16 resistance (n=244) | Nagpur 2015-16 Resistance (n=112) |
|----------------------|-----------------------------------------------|-----------------------------------------------|---------------------|-----------------------------------------------|----------------------------------|
| S                    | 7.60%                                         | 3.03%                                         | <0.05               | 4.50%                                         | 6.25%                            |
| H                    | 15.20%                                        | 2.27%                                         | <0.05               | 2.45%                                         | 2.67%                            |
| R                    | 0.50%                                         | 0.75%                                         | <0.05               | 0.81%                                         | 0.8%                             |
| EB                   | 1.00%                                         | 0.75%                                         | <0.05               | 0.40%                                         | 0%                               |
| Overall susceptible  | 80.20%                                        | 94.69%                                        | <0.05               | 93.44%                                        | 91.96%                           |
| HR(MDR)              | 0.50%                                         | 0.75%                                         | <0.05               | 0.81%                                         | 0.89%                            |
| Mono S resistant     | 4.60%                                         | 1.51%                                         | <0.05               | 4.37%                                         | 4.46%                            |
| Mono H resistant     | 10.70%                                        | 0.75%                                         | <0.05               | 0.81%                                         | 0.89%                            |
| Two drugs resistance | 4.60%                                         | 3.0%                                          | <0.05               | 2.42%                                         | 1.78%                            |
DOTS, MDR-TB prevalence in Delhi has not risen over the years and continues to be low among NPTB cases.

The recent report on the first national anti-tuberculosis drug resistance survey 2014-2016\textsuperscript{12} using liquid culture (MGIT 960) has reported MDR-TB to be 2.84\% (CI 95\%, 2.27-3.5\%) among the new pulmonary TB patients. Any resistance to streptomycin, isoniazid, rifampicin and ethambutol was 6.88\% (6.01-7.84\%), 11.06\% (9.97-12.22\%), 2.84\% (2.28-3.49\%) and 2.28\% (1.78-2.88\%) respectively. Similar values in our study area are even lower than the lowest range quoted in this national survey reflecting on the efficacy of the control programme in the area.

Earlier to the implementation of RNTCP in India the range for MDR-TB in new smear positives was described as 0-5\%.\textsuperscript{13} It was reported as 4.4\% in North Arcot in 1989-1998 and 5.3\% in Wardha district 1982-89.\textsuperscript{14} Even any resistance to rifampicin was respectively 11.8\% and 8\% in the two districts and isoniazid was 21\% and 19\%. Later when WHO/IUATLD study was conducted in Wardha, the rifampicin resistance in the district was reported as 0.5\%.\textsuperscript{4} The reason for high resistance reported earlier from many centres can be attributed probably to the use of non-standardized methods with no quality control measures.

The present study in Wardha and the WHO/IUATLD study have both been carried out in certified laboratories. Thus the data from the present study, using the same methodology and comparing the population in the same area does reveal that drug resistance continues to be low and there has been no significant change in the multidrug resistance, if at all, the mono resistance among the NPTB patients has shown significant fall (Table 3).

Data on fluoroquinolone (FQ) resistance in new cases is limited. Any resistance to ofloxacin, the only fluoroquinolone tested in the present study, was 0.85\% which is much lower than 10.4\% reported in new cases from Tamil Nadu.\textsuperscript{15} A drug resistance surveillance (DRS) study from Gujarat in 2009, reported FQ mono-resistance to be around 24\% with no significant difference between new and retreatment TB cases.\textsuperscript{16} The national survey\textsuperscript{12} has reported it to be 3.72\% (3.08-4.45) among the new smear positives and 6.29 (5.23-7.48) among the previously treated patients and has expressed concern over the developing high resistance rate of fluoroquinolones among the MDR cases (21.82\%). Recently in 2018 Rohini Sharma et al from All India Institute of Medical Sciences, Delhi\textsuperscript{17} have reported using MGIT 960 liquid media, only 1.8\% mono resistance in their new TB cases (13/728) and among re-treated drug sensitive TB cases it was 5.9\% (22/371). The overall FQ mono-resistance among drug sensitive TB cases including new and re-treated TB cases was 3.1\%. Mono resistance in our study was only 0.4\%. The use of this drug in our district, which is mostly rural in nature, is probably less than that in metropolis where the drug is easily available and very frequently recommended by the private practitioners. Fluoroquinolones and now bedaquiline and other upcoming drugs like delamanid, should be used with extreme care and reservation as they will essentially be the life line drugs for the survival and cure of MDR cases.

Isolates differ from one geographical area to another and molecular epidemiology is used to trace the prevalence and source of infection. There is no published data on the mutational pattern of the resistant isolates from our study area. The commonest mutational pattern reported from other areas for rifampicin resistance\textsuperscript{18-22} has been MUT-3 band for codon S531L, accounting for 36-56\% of all rpoB gene mutations which was the same as one of our MDR isolate. The second most prevalent strain all over is with mutation in WT-7 codon 526 of the rpo B gene. Our second isolate showed a different pattern with all 513 to 531 codons missing in all the four bands WT4, WT6, WT7 and WT8 which is an unusual.

The studies on previously treated patients from India i.e., Delhi,\textsuperscript{23,24} Gujarat,\textsuperscript{25} Himachal Pradesh\textsuperscript{26} and a multicentric study conducted in Ahemdabad,\textsuperscript{27} have all reported MUT-3 S531L mutation in rpoB gene to be the most prevalent circulating strains for rifampicin resistance. The frequency of mutation in the rpoB gene with S531L pattern reported in MDR-TB isolates was 48.9\%, 58.2\%, 74\%, 62.22\% and 47\%, respectively in the studies mentioned above. The second prevalent strain had mutational pattern MUT-2 H526D.

The resistance to isoniazid is of two types—the high level resistance due to mutation in the katG gene and low level resistance due to mutation in inhA promoter region. High level resistance to isoniazid is most prevalent in India\textsuperscript{28,29} the pattern being mutation in codon S315T, less common are strains showing low level resistance with mutation in inhA C15T promoter region. Among six of our isoniazid resistant strains, four showed high level resistance with mutation in katG at S315T and two isolates showed low resistance in inhA at C15T of the promoter region, one of which was an MDR isolate. Being a study only on newly detected cases, the number of isolates detected are few. However, future mutational studies should be undertaken on all previously treated patients as the isolates generated by them are the actual strains circulating in the community and responsible for initial drug resistance. It is expected that even in them the predominant detected mutations would be the ones mentioned above.

5. Conclusion

In order to monitor the efficacy of the national control programmes repeat drug resistance surveys have been advocated so as to detect the trends in the development of resistance and institute steps if necessary, to reverse the situation. Though India has just completed its first such survey at National level, this exercise is operationally
difficult. Small studies like the present one can act as great contributors since follow up studies available are very few. The present resurvey has brought out that the drug resistance among new pulmonary TB cases in Wardha district continues to be low and that the RNTCP has done well. Similarly the present figures for Nagpur are also very reassuring and, though the numbers are very small, the mutational patterns as derived from LPA are much in line with those reported from other parts of the country.

6. Acknowledgement

The authors are grateful to IRL Nagpur for conducting the LPA on the isolates and to RNTCP Maharashtra for giving financial aid for this work. The authors are also grateful to Central TB Division for sanctioning the TB Recurrence study which enabled us to get and process the Mycobacterium tuberculosis isolates from the new smear positive pulmonary tuberculosis patients from the two TUs. The authors are also thankful to the management of Mahatma Gandhi Institute of Medical Sciences for permitting the research.

7. Conflict of Interest

The Authors declare that they have no conflict of interest.

8. Source of Funding

None.

References

1. WHO Tuberculosis Global Report; 2017. Available from: http://www.who.int/tb/publications/global_report/en/.
2. Revised National Tuberculosis Control programme 2005; Technical and operational guidelines for tuberculosis Control. health.bih.nic.in/Docs/Guidelines-TB-Control.pdf.
3. RNTCP Status Report, TB India: Central TB Division, Directorate General of Health Services; 2003. Available from: https://tbcindia.gov.in.
4. Anti-tuberculosis drug resistance in the world: Third global report/WHO/CDs/TB/WHO/IATLTD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1999-2002; Third global report WHO/CDs/TB 2004.
5. Revised National TB Control Programme:Manual of Standard Operating Procedures (SOPs) Culture of Mycobacterium tuberculosis and Drug Susceptibility Testing on solid Medium; 2009.
6. Velayutham B, Chadhavik, Singla N, Narang P, Gangadhar RV, Nair S, et al. Recurrence of tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated under the Revised National Tuberculosis Control Programme, India: A multicentric prospective study. PLoS One. 2018;13(7):200150. doi:10.1371/journal.pone.0200150.
7. Revised National Tuberculosis Control Programme: Manual for laboratory technician ; 1999. Available from: www.phls.gov.bt/...,Standard-Manual-For-Laboratory-Technicians.
8. Tuberculosis Research Centre: Standard operating procedure for Mycobacteriology laboratory; 2010.
9. World Health Organization : Guideline for drug susceptibility testing for second line anti-tuberculosis drugs for DOTS-PLUS; 2001.
10. Madhuri K, Deshpande S, Dharmashale S, Bharadwaj R. Utility of Line Probe assay for the early of multidrug resistant pulmonary tuberculosis. J Global Infect Dis. 2015;7(2):60–5.
11. Sharma SK, Kaushik G, Jha B, George N, Arora SK, Gupta D, et al. Prevalence of multidrug-resistant tuberculosis among newly diagnosed cases of sputum-positive pulmonary tuberculosis. Indian J Med Res. 2011;133(3):308–11.
12. Report of the first National anti-tuberculosis drug resistance survey India 2014-2016. WHO and Ministry of Health and Family Welfare Government of India-released on 24th March 2018. Available from: https://tbcindia.gov.in/showfile.php?id=3315.
13. Paramasivam CN, Venkataraman P. Drug resistance in tuberculosis in India. Indian J Med Res. 2004;120(4):377–89.
14. Nayyar S, Narang P, Tyagi NK, Jajoo UN, Gupte MD, Dwivedi MP, et al. Field trial of short term intermittent chemotherapy against tuberculosis. Department of Community Medicine, Medicine & Microbiology, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha, Maharashtra, 1982–1989. Project [No. 5/8/5/2/81/ECD-1 ID No.-8102650]; 1989 Report submitted to Indian Council of Medical Research, New Delhi. 1982.;
15. Selvakumar N, Kumar V, Balaji S, Prabuseenivasan S, Radhakrishnan R, Gomathi S, et al. High Rates of Ofloxacin Resistance in Mycobacterium tuberculosis among Both New and Previously Treated Patients in Tamil Nadu. South India PLoS ONE. 2015;10(3):117421. doi:10.1371/journal.pone.0117421.
16. Ramachandran R, Nalinii S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis. 2009;13(9):1154–60.
17. Sharma R, Singh BK, Kumar P, Ramachandran R, Jorwala P. Presence of Fluoroquinolone mono-resistance among drug-sensitive Mycobacterium tuberculosis isolates: An alarming trend and implications. Clin Epidemiol Global Health. 2018;7(3):363–6. doi:10.1016/cgeh.2018.05.003.
18. Barnard M, Albert H, Coetzee G, Brien RO, Bosman ME. Rapid Molecular Screening for Multidrug resistant tuberculosis in a high volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008;177(7):787–92.
19. Meaza A, Kebede A, Yaregal Z, Dawne Z, Mogu S, Yeneew B, et al. Evaluation of genotype MTBDR plus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infect Dis. 2017;17(1):280. doi:10.1186/s12879-017-2389-6.
20. Miotto P, Piana F, Penati V, Canducci F, Migliori GB. Cirillo DM Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Clinical Strains Isolated in sin Italy. J Clin Microbiol. 2006;44(7):2485–91.
21. Bartfai Z, Somoskovi A, Kodmon C, Szabo N, Puskas E, Kosztolanyi L, et al. Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay. J Clin Microbiol. 2001;39(10):3736–9.
22. Hirano K, Chiyoi A, Takahashi M. Mutations in the rpoB Gene of Rifampin-Resistant Mycobacterium tuberculosis Strains Isolated Mostly in Asian Countries and Their Rapid Detection by Line Probe Assay. J Clin Microbiol. 1999;37(8):2663–6.
23. Kumar P, Babooni V, Singh S. Genetic mutations associated with rifampicin and isoniazid resistance in MDR-TB patients in North-West India. India Int J Tuberc Lung Dis. 2015;19(4):434–9.
24. Singhal R, Myneedu VP, Arora J, Singh N, Bhalla M, Verma A, et al. Early detection of multi-drug resistance and common mutations in Mycobacterium tuberculosis isolates from Delhi using GenoTypeMTBDRPlus assay. Indian J Med Microbiol. 2015;33(3):46–52. doi:10.1007/s12029-015-0725-2.
25. Katara NC, Ghedia BJ, Sinha M. Rapid Detection of Mutations in rpoB Gene of Rifampicin Resistant Mycobacterium tuberculosisStrains by Line Probe Assay in GIGG Hospital. Int J Curr Microbiol App Sci. 2016;5(9):44–53.
26. Thakur C, Thakur V, Gupta AK. Detecting mutation pattern of drug resistant Mycobacterium tuberculosis isolates in Himachal Pradesh using GenoType®MTBDRplus assay. Indian J Microbiol. 2015;53(4):547–53.
27. Raizada N, Sachdeva KS, Chauhan DS, Malhotra B, Kishore R, Dave PV, et al. A Multi-Site Validation in India of the Line Probe Assay for
the Rapid Diagnosis of Multi-Drug Resistant Tuberculosis Directly from Sputum Specimens. *PLoS One*. 2014;9(2):88626. doi:10.1371/journal.pone.0088626.

Singh BK, Sharma SK, Sharma R, Sreenivas V, Myneedu VP, Kohli M, et al. Diagnostic utility of a line probe assay for multidrug resistant-TB in smear-negative pulmonary tuberculosis. *PLoS ONE*. 2017;12(8):e0182988. doi:10.1371/journal.pone.0182988.

Yadav RN, Singh BK, Sharma SK, Sharma R, Soneja M, Sreenivas V, et al. Comparative Evaluation of GenoType MTBDR plus Line Probe Assay with Solid Culture Method in Early Diagnosis of Multidrug Resistant Tuberculosis (MDR-TB) at a Tertiary Care Centre in India. *PLoS One*. 2013;8(9):72036. doi:10.1371/journal.pone.0072036.

**Author biography**

Supriya Meshram, Assistant Professor

Pratibha Narang, Emeritus Professor

Farah Mohammed, Consultant Microbiologist & Lab Director

Rahul Narang, Professor and Head

N S Gomathi, Principal TECH Officer

Ajay Dawale, DTO

---

Cite this article: Meshram S, Narang P, Mohammed F, Narang R, Gomathi NS, Dawale A. Drug resistance in tuberculosis- resurvey in Wardha district, India after implementation of revised national TB control program. *IP Int J Med Microbiol Trop Dis* 2021;7(3):192-198.